Vladislav Sandler
Net worth: 941 588 $ as of 31/07/2026
Net worth: 941 588 $ as of 31/07/2026
Vladislav Sandler is the founder of HemoGenyx Pharmaceuticals Plc, founded in 2012, holding the title of Chief Executive Officer & Executive Director since 2017.
Dr. Sandler is also the founder of Hemogenyx Pharmaceuticals LLC..
Dr. Sandler currently holds the position of Director at Hemogenyx UK Ltd. since 2017.
Since 2019, Dr. Sandler has been Chief Executive & Scientific Officer at Immugenyx LLC.
Dr. Sandler is an Assistant Professor at the State University of New York at Downstate Medical Center.
Dr. Sandler is a Member of The International Society for Stem Cell Research.
Dr. Sandler earned a doctorate degree from the University of British Columbia.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 31/12/2025 | 113,861 ( 1.67% ) | 941 588 $ | 31/07/2026 |
| Companies | Position | Start |
|---|---|---|
| HEMOGENYX PHARMACEUTICALS PLC | Founder | 01/01/2012 |
Hemogenyx Pharmaceuticals LLC
Hemogenyx Pharmaceuticals LLC BiotechnologyHealth Technology Operates as biopharmaceutical company that develops treatment for blood diseases | Founder | - |
State University of New York at Downstate Medical Center
State University of New York at Downstate Medical Center Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
The International Society for Stem Cell Research
The International Society for Stem Cell Research The International Society for Stem Cell Research (ISSCR) is a nonprofit organization dedicated to advancing stem cell science and its applications to human health. The non-profit company is based in Deerfield, IL. It represents nearly 5,000 members from over 80 countries, including scientists, educators, ethicists, clinicians, and business leaders. ISSCR promotes rigorous and ethical research through the development of international guidelines and quality standards, and provides resources such as the open-access journal Stem Cell Reports, standards documents for human stem cell use, and educational programs including annual meetings, symposia, webinars, and on-demand scientific content. The society supports workforce development by engaging early career scientists and trainees, fosters collaboration through a directory of stem cell societies and institutes, and conducts advocacy and policy efforts to provide scientific input to regulatory agencies and combat unproven stem cell therapies. ISSCR emphasizes equity, diversity, and inclusion, and offers resources for researchers, clinicians, educators, patients, and policymakers. The organization facilitates access to funding opportunities, supports continuing education, and promotes public and patient education. Membership benefits include networking, reduced fees for meetings and publishing, and access to scientific content. | Corporate Officer/Principal | - |
Hemogenyx UK Ltd.
Hemogenyx UK Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Director/Board Member | 04/10/2017 |
Immugenyx LLC
Immugenyx LLC BiotechnologyHealth Technology Operates biotechnology company | Chief Executive Officer | 01/01/2019 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 7 |
|---|---|
University of British Columbia
University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
State University of New York at Downstate Medical Center
State University of New York at Downstate Medical Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The International Society for Stem Cell Research
The International Society for Stem Cell Research The International Society for Stem Cell Research (ISSCR) is a nonprofit organization dedicated to advancing stem cell science and its applications to human health. The non-profit company is based in Deerfield, IL. It represents nearly 5,000 members from over 80 countries, including scientists, educators, ethicists, clinicians, and business leaders. ISSCR promotes rigorous and ethical research through the development of international guidelines and quality standards, and provides resources such as the open-access journal Stem Cell Reports, standards documents for human stem cell use, and educational programs including annual meetings, symposia, webinars, and on-demand scientific content. The society supports workforce development by engaging early career scientists and trainees, fosters collaboration through a directory of stem cell societies and institutes, and conducts advocacy and policy efforts to provide scientific input to regulatory agencies and combat unproven stem cell therapies. ISSCR emphasizes equity, diversity, and inclusion, and offers resources for researchers, clinicians, educators, patients, and policymakers. The organization facilitates access to funding opportunities, supports continuing education, and promotes public and patient education. Membership benefits include networking, reduced fees for meetings and publishing, and access to scientific content. | |
Hemogenyx Pharmaceuticals LLC
Hemogenyx Pharmaceuticals LLC BiotechnologyHealth Technology Operates as biopharmaceutical company that develops treatment for blood diseases | Health Technology |
HemoGenyx Pharmaceuticals Plc
HemoGenyx Pharmaceuticals Plc BiotechnologyHealth Technology Operates as biopharmaceutical company that develops treatment for blood diseases | Health Technology |
Hemogenyx UK Ltd.
Hemogenyx UK Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
Immugenyx LLC
Immugenyx LLC BiotechnologyHealth Technology Operates biotechnology company | Health Technology |
Select your edition
All financial news and data tailored to specific country editions